Evidence map›Paper›PMID 35197142›Full record

ArticlePsychological medicine2023

Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study.

Arsime Demjaha, Silvana Galderisi, Birthe Glenthøj, Celso Arango, Armida Mucci, Andrew Lawrence, Owen O'Daly, Matthew Kempton, Simone Ciufolini, Lone Baandrup and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Psychological medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 6 countries.

Arsime DemjahaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Silvana GalderisiDepartment of Psychiatry, University of Campania Luigi Vanvitelli, Caserta, Italy.
Birthe GlenthøjFaculty of Health and Medical Sciences, Department of Clinical Medicine, Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, University of Copenhagen, Copenhagen, Denmark.
Celso ArangoDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón. IiSGM, CIBERSAM. School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Armida MucciDepartment of Psychiatry, University of Campania Luigi Vanvitelli, Caserta, Italy.
Andrew LawrenceDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Owen O'DalyDepartment of Neuroimaging, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
Matthew KemptonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Simone CiufoliniDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Lone BaandrupFaculty of Health and Medical Sciences, Department of Clinical Medicine, Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, University of Copenhagen, Copenhagen, Denmark.
Bjørn H EbdrupFaculty of Health and Medical Sciences, Department of Clinical Medicine, Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Center Glostrup, University of Copenhagen, Copenhagen, Denmark.
Roberto Rodriguez-JimenezDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón. IiSGM, CIBERSAM. School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Maria Diaz-MarsaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón. IiSGM, CIBERSAM. School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Covadonga Martinez Díaz-CanejaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health. Hospital General Universitario Gregorio Marañón. IiSGM, CIBERSAM. School of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Inge Winter van RossumDepartment of Psychiatry, Brain Center Rudolf Magnus, Utrecht, Netherlands.
Rene KahnDepartment of Psychiatry, Brain Center Rudolf Magnus, Utrecht, Netherlands.
Paola DazzanDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
South London and Maudsley NHS Foundation Trust · GBCentro de Investigación Biomédica en Red de Salud Mental · ESHersenstichting · NLKing's College London · GBNational Institute for Health Research · GBUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Copenhagen · DKGlostrup Hospital · DKHospital General Universitario Gregorio Marañón · ESUniversidad Complutense de Madrid · ES

Funding

Medical Research Council MC_PC_11003MRF_ C0439
6 · The paper itself

Abstract

backgroundNegative symptoms are one of the most incapacitating features of Schizophrenia but their pathophysiology remains unclear. They have been linked to alterations in grey matter in several brain regions, but findings have been inconsistent. This may reflect the investigation of relatively small patient samples, and the confounding effects of chronic illness and exposure to antipsychotic medication. We sought to address these issues by investigating concurrently grey matter volumes (GMV) and cortical thickness (CTh) in a large sample of antipsychotic-naïve or minimally treated patients with First-Episode Schizophrenia (FES).

methodsT1-weighted structural MRI brain scans were acquired from 180 antipsychotic-naïve or minimally treated patients recruited as part of the OPTiMiSE study. The sample was stratified into subgroups with (

resultsThe presence of PMN symptoms was associated with larger left inferior orbitofrontal volume (

conclusionsThe findings highlight the role of orbitofrontal and temporal cortices in the pathogenesis of negative symptoms of Schizophrenia. As they were evident in generally untreated FEP patients, the results are unlikely to be related to effects of previous treatment or illness chronicity.

Indexed as

Antipsychotic AgentsSchizophreniaBrainGray MatterHumansMagnetic Resonance ImagingTemporal LobeAntipsychotic AgentsCortical thicknessfirst-episode psychosisFreeSurfernegative symptomsvoxel-based morphometry

Identifiers

PMID35197142
PMCPMC10277764
OpenAlexW4213436721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.